This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:protocol:olmesartan [11.27.2018] – [Other beneficial effects] sallieq | home:protocol:olmesartan [04.20.2019] – [Other beneficial effects] sallieq | ||
---|---|---|---|
Line 123: | Line 123: | ||
* inhibit liver fibrosis and aid liver healing(({{pubmed> | * inhibit liver fibrosis and aid liver healing(({{pubmed> | ||
* reduce insulin resistance in rats(({{pubmed> | * reduce insulin resistance in rats(({{pubmed> | ||
- | * 6 mg/kg olmesartan reduces the inflammatory process and bone loss in rats(({{pubmed> | + | * 6 mg/kg olmesartan reduces the inflammatory process and periodontal |
* protect the mitochondria from age-associated damage from oxidation(({{pubmed> | * protect the mitochondria from age-associated damage from oxidation(({{pubmed> | ||
* play a protective role against proliferative diabetic retinopathy (({{pubmed> | * play a protective role against proliferative diabetic retinopathy (({{pubmed> | ||
Line 146: | Line 147: | ||
* act as an antiarrhythmic(({{pubmed> | * act as an antiarrhythmic(({{pubmed> | ||
* block the production of Angiotensin II, thus improving mortality rates in heart failure patients(({{pubmed> | * block the production of Angiotensin II, thus improving mortality rates in heart failure patients(({{pubmed> | ||
+ | * This study demonstrated that olmesartan reduced angiotensin II and aldosterone levels more effectively than azilsartan, resulting in a stable antihypertensive effect. Olmesartan also had an inhibitory effect on cardiac hypertrophy. Accordingly, | ||
< | < | ||
Line 169: | Line 171: | ||
* in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition (({{pubmed> | * in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition (({{pubmed> | ||
* results suggest olmesartan can help decrease plasma AGE levels in patients on HD (({{pubmed> | * results suggest olmesartan can help decrease plasma AGE levels in patients on HD (({{pubmed> | ||
- | * renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed> | + | * renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed> |
* olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects | * olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects | ||